Spots Global Cancer Trial Database for tivantinib
Every month we try and update this database with for tivantinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT01075048 | Metastatic Colo... | Tivantinib Placebo Cetuximab Irinotecan | 18 Years - | Daiichi Sankyo | |
| Effect of Tivantinib on the QTC Interval in Cancer Subjects | NCT01699061 | Solid Tumors | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects | NCT01517399 | Solid Tumors | tivantinib omeprazole s-warfarin caffeine vitamin K digoxin midazolam | 18 Years - | Daiichi Sankyo | |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT01749384 | Solid Neoplasm | Bevacizumab Laboratory Biom... Pharmacological... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | NCT01688973 | Recurrent Renal... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... | Erlotinib Hydro... Laboratory Biom... Tivantinib | - | National Cancer Institute (NCI) | |
| Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | NCT01654965 | Adult Solid Neo... | Laboratory Biom... Pegfilgrastim Pharmacological... Tivantinib Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | NCT01178411 | Advanced Solid ... | Tivantinib Anti-Cancer Com... | 13 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects | NCT01892527 | Colorectal Canc... C-met Overexpre... | Tivantinib (ARQ... | 18 Years - 80 Years | Istituto Clinico Humanitas | |
| Effect of Tivantinib on the QTC Interval in Cancer Subjects | NCT01699061 | Solid Tumors | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery | NCT01625156 | Adult Solid Neo... | Laboratory Biom... Pharmacological... Temsirolimus Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | NCT01244191 | Non Squamous, N... | Tivantinib Placebo Erlotinib | 18 Years - | Daiichi Sankyo | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT01749384 | Solid Neoplasm | Bevacizumab Laboratory Biom... Pharmacological... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors | NCT01725191 | Childhood Solid... | Laboratory Biom... Pharmacological... Tivantinib | 13 Months - 21 Years | National Cancer Institute (NCI) | |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
